April 01, 2015
A Massachusetts federal judge on Tuesday tossed a proposed putative securities class action accusing Sarepta Therapeutics Inc. of misleading investors over the chances of its muscular dystrophy drug eteplirsen hitting the market, saying that the biopharma company couched its optimistic statements with proper disclosures.
January 28, 2014
A Sarepta Pharmaceuticals Inc. shareholder filed a class action against the company in Massachusetts federal court Monday, alleging it intentionally misled investors about muscular dystrophy drug eteplirsen's chances of hitting the open market.